Multi-cohort validation demonstrated robust prognostic capacity of PLIN2 expression, achieving time-dependent AUCs of 0.695–0.814 (1-year), 0.621–0.750 (3-year), and 0.626–0.754 (5-year) across TCGA-CRC (n = 594, 10-fold cross-validation), GSE17536 (n = 177), GSE17538 (n = 232), and GSE39582 (n = 577) cohorts (Fig. S4I–L). This evidence concerns the gene PLIN2 and colorectal carcinoma.